Lundbeck Posts Promising Phase IIb Data For Bocunebart In Migraine Prevention  
Positive Phase IIb data positions Lundbeck’s anti-PACAP antibody bocunebart for Phase III discussions, potentially expanding the company’s migraine franchise beyond its CGRP therapy Vyepti.
Scrip - February 13, 2026

Ipsen Chief Calls On Europe To Improve Access
David Loew highlights the problem that around half of the drugs approved by the European Medicines Agency are not actually launched.
Scrip - February 13, 2026

Deals Shaping The Medtech And Diagnostics Industries, January 2026
An interactive look at medtech and diagnostics deals made during January 2026. Data courtesy of Biomedtracker.
Medtech Insight - February 13, 2026

Does Organon’s Biosimilars Review Point To Deeper Internal Control Challenges?
Organon’s management declined to discuss the ongoing review, leaving analysts questioning whether the latest issue could signal broader governance or oversight challenges.
Generics Bulletin - February 13, 2026

National HealthTech Access Programme To Be Key Enabler Of New NHS Commercial Strategy In UK
UK medtech pulls up to NICE’s top table as two-year old Rules-Based Pathway gets a rebrand while device, diagnostic and digital innovators see a bigger TA target come into sight. Meanwhile, the NHS is asking for input into a new commercial strategy.
Medtech Insight - February 13, 2026

Executives On The Move: HighTide Therapeutics Gets A New CMO From AstraZeneca
Recent moves in the industry include changes at the top at Spruce Biosciences, Aptevo Therapeutics and Primmune Therapeutics, plus Moderna get a new chief development officer.
Scrip - February 13, 2026

Teva And GSK Settle Skinny-Label Dispute
Long-running litigation between Teva and GSK over a skinny-label generic carvedilol version of Coreg has ended not with a bang but with a whimper, after the two firms settled on undisclosed terms.
Generics Bulletin - February 13, 2026

Biosimilar Darzalex Progress Caps Busy Few Months For Shanghai Henlius Biotech
Shanghai Henlius Biotech has enjoyed a busy few months advancing multiple biosimilar candidates, including daratumumab, ipilimumab, and nivolumab.
Generics Bulletin - February 13, 2026

Aurobindo: Biosimilars Inflection Point Pushed, gPomalyst Launch Set For Q4
Aurobindo has pushed its projection of an inflection point for biosimilars ahead by a year to FY29 but plans to launch a generic to BMS blockbuster Pomalyst (pomalidomide) in the current quarter. Meanwhile, anti-competitive pricing of penicillin-G by China should now cause less harm
Scrip - February 13, 2026

BD Completes Waters Deal, Deploys $4bn Proceeds To Buybacks And Debt Reduction
Waters will apply its commercial execution model to the spun-off BD business to drive efficiencies across sales, service, product launches and digital channels.
Medtech Insight - February 13, 2026

US Consumer Health Industry Hires: Edible Brands, Happyactually, Nowadays, RäFoods, DoTerra, More
NPA appoints SVP membership; Edible Brands promotes Angela Johnson to CMO; happyactually has medical chief; Nowadays adds reg affairs director; doTerra appoints EVP, innovation; RäFoods names president/CEO; Genesis Lifestyle Medicine adds VP operations; and Hany Salama leads Nutra-Med Packaging.
HBW Insight - February 13, 2026

Japan Q3 Roundup: Weak Yen Boosts Solid Overseas Growth For Mainstays
Major Japanese pharma companies' results for the period ended Dec.31 were marked by generally strong overseas growth for mainstays, boosted by currency effects.
Scrip - February 13, 2026